论文部分内容阅读
目的分析卡马西平治疗癫痫的血药浓度,为临床合理用药提供依据。方法选择2009年1月—2013年6月采用卡马西平治疗的患者248例,均给予卡马西平0.1g/次口服,3次/d,服用14 d后可达到稳态血药浓度,于清晨用药前取静脉血2 ml,高效液相色谱法测定稳态谷浓度。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果卡马西平血药浓度<4μg/ml有效率92.6%,4~12μg/ml有效率90.5%,≥12μg/ml有效率65.4%,随着血药浓度的升高,有效率反而下降,比较差异有统计学意义(P<0.05)。联合用药时有25.7%的患者血药浓度<4μg/ml。结论使用卡马西平时应监测血药浓度,根据个体情况调整剂量,使卡马西平得到更安全、合理、有效的应用。
Objective To analyze the blood concentration of carbamazepine in the treatment of epilepsy and provide the basis for clinical rational drug use. Methods A total of 248 patients treated with carbamazepine from January 2009 to June 2013 were given carbamazepine 0.1 g / orally orally for 3 times daily for 14 days. Early morning medication venous blood 2 ml, high-performance liquid chromatography determination of steady-state trough concentration. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results The effective rate of carbamazepine plasma concentration <4μg / ml was 92.6%, the effective rate of 4 ~ 12μg / ml was 90.5%, and the effective rate of ≥ 12μg / ml was 65.4%. The effective rate decreased with the increase of plasma concentration The difference was statistically significant (P <0.05). When combined, 25.7% of patients had plasma concentrations <4 μg / ml. Conclusions Carbamazepine should be used to monitor the plasma concentration and adjust the dose according to individual circumstances so as to make carbamazepine safer, more reasonable and effective.